NURS 676 ADVANCED PHARMACOLOGY
MIDTERM EXAM 2026/2027 | WCU VERIFIED
QUESTIONS & ANSWERS | APRN
PHARMACOTHERAPEUTICS, CLINICAL
PRESCRIBING, PHARMACOKINETICS &
PHARMACODYNAMICS REVIEW GUIDE
• This verified exam prep guide contains 280 high-yield multiple-choice questions
covering all core domains of NURS 676 Advanced Pharmacology for APRN practice
at WCU.
• Use this material by attempting each question independently before revealing the
answer — the correct option is bolded and highlighted, followed by a clear EXPERT
RATIONALE to reinforce clinical reasoning.
NURS 676 ADVANCED PHARMACOLOGY MIDTERM EXAM 2026/2027 WCU
VERIFIED QUESTIONS & ANSWERS APRN PHARMACOTHERAPEUTICS | CLINICAL
PRESCRIBING | PHARMACOKINETICS & PHARMACODYNAMICS
1. A drug with a high volume of distribution (Vd) is most likely to:
A. Remain primarily in the bloodstream
B. Be rapidly excreted by the kidneys
C. Have a short duration of action
D. Be extensively distributed into peripheral tissues
E. Bind strongly to plasma proteins without tissue penetration
Correct Answer: D – Be extensively distributed into peripheral tissues
EXPERT RATIONALE: A high Vd indicates that the drug distributes widely into
body tissues rather than staying in the plasma. Lipophilic drugs tend to have a high
Vd because they readily cross cell membranes and accumulate in fat and muscle
tissue.
,2. Which pharmacokinetic parameter best describes the time required for the
plasma concentration of a drug to decrease by 50%?
A. Volume of distribution
B. Bioavailability
C. Clearance
D. Loading dose
E. Half-life (t½)
Correct Answer: E – Half-life (t½)
EXPERT RATIONALE: The half-life is the time it takes for the plasma
concentration of a drug to fall by half. It determines dosing intervals and the time to
reach steady state (approximately 4–5 half-lives).
3. A patient takes a drug that undergoes extensive first-pass metabolism. This
means:
A. The drug is rapidly distributed to the CNS
B. The drug has a high volume of distribution
C. The drug is activated in the kidneys before systemic circulation
D. A significant portion of the drug is metabolized in the liver before reaching
systemic circulation
E. The drug is primarily eliminated through bile
Correct Answer: D – A significant portion of the drug is metabolized in the
liver before reaching systemic circulation
EXPERT RATIONALE: First-pass metabolism occurs when an orally administered
drug is absorbed from the GI tract and passes through the portal circulation to the
liver, where it undergoes significant biotransformation before reaching systemic
circulation, reducing bioavailability.
,4. Which of the following best defines bioavailability?
A. The rate at which a drug is eliminated from the body
B. The ability of a drug to bind to its receptor
C. The time required to reach peak plasma concentration
D. The percentage of drug that reaches the target organ
E. The fraction of an administered drug that reaches systemic circulation in
an unchanged form
Correct Answer: E – The fraction of an administered drug that reaches
systemic circulation in an unchanged form
EXPERT RATIONALE: Bioavailability (F) reflects how much of the administered
dose actually reaches systemic circulation. IV administration yields 100%
bioavailability; oral bioavailability is reduced by first-pass metabolism and
incomplete absorption.
5. An APRN prescribes a loading dose for a patient. The primary reason for a
loading dose is to:
A. Reduce the risk of drug toxicity
B. Prolong the drug's half-life
C. Decrease the volume of distribution
D. Minimize first-pass metabolism
E. Rapidly achieve therapeutic plasma concentrations
Correct Answer: E – Rapidly achieve therapeutic plasma concentrations
EXPERT RATIONALE: A loading dose is a higher initial dose given to quickly
bring plasma drug levels to the therapeutic range, especially for drugs with long
half-lives where waiting for steady state would delay clinical effect.
, 6. Which cytochrome P450 enzyme is responsible for metabolizing the
majority of clinically used drugs?
A. CYP1A2
B. CYP2C9
C. CYP2D6
D. CYP2E1
E. CYP3A4
Correct Answer: E – CYP3A4
EXPERT RATIONALE: CYP3A4 is the most abundant hepatic and intestinal CYP
enzyme and is responsible for metabolizing approximately 50% of all clinically used
drugs. It is a common site for drug–drug interactions.
7. A patient on warfarin is started on rifampin. What is the expected
pharmacokinetic interaction?
A. Rifampin inhibits CYP2C9, increasing warfarin levels
B. Rifampin displaces warfarin from plasma proteins
C. Rifampin decreases warfarin absorption
D. Rifampin inhibits renal elimination of warfarin
E. Rifampin induces CYP enzymes, decreasing warfarin plasma levels
Correct Answer: E – Rifampin induces CYP enzymes, decreasing warfarin
plasma levels
EXPERT RATIONALE: Rifampin is a potent inducer of CYP3A4 and CYP2C9.
When co-administered with warfarin (metabolized by CYP2C9), rifampin increases
warfarin metabolism, lowering plasma levels and reducing anticoagulant effect,
increasing clotting risk.
MIDTERM EXAM 2026/2027 | WCU VERIFIED
QUESTIONS & ANSWERS | APRN
PHARMACOTHERAPEUTICS, CLINICAL
PRESCRIBING, PHARMACOKINETICS &
PHARMACODYNAMICS REVIEW GUIDE
• This verified exam prep guide contains 280 high-yield multiple-choice questions
covering all core domains of NURS 676 Advanced Pharmacology for APRN practice
at WCU.
• Use this material by attempting each question independently before revealing the
answer — the correct option is bolded and highlighted, followed by a clear EXPERT
RATIONALE to reinforce clinical reasoning.
NURS 676 ADVANCED PHARMACOLOGY MIDTERM EXAM 2026/2027 WCU
VERIFIED QUESTIONS & ANSWERS APRN PHARMACOTHERAPEUTICS | CLINICAL
PRESCRIBING | PHARMACOKINETICS & PHARMACODYNAMICS
1. A drug with a high volume of distribution (Vd) is most likely to:
A. Remain primarily in the bloodstream
B. Be rapidly excreted by the kidneys
C. Have a short duration of action
D. Be extensively distributed into peripheral tissues
E. Bind strongly to plasma proteins without tissue penetration
Correct Answer: D – Be extensively distributed into peripheral tissues
EXPERT RATIONALE: A high Vd indicates that the drug distributes widely into
body tissues rather than staying in the plasma. Lipophilic drugs tend to have a high
Vd because they readily cross cell membranes and accumulate in fat and muscle
tissue.
,2. Which pharmacokinetic parameter best describes the time required for the
plasma concentration of a drug to decrease by 50%?
A. Volume of distribution
B. Bioavailability
C. Clearance
D. Loading dose
E. Half-life (t½)
Correct Answer: E – Half-life (t½)
EXPERT RATIONALE: The half-life is the time it takes for the plasma
concentration of a drug to fall by half. It determines dosing intervals and the time to
reach steady state (approximately 4–5 half-lives).
3. A patient takes a drug that undergoes extensive first-pass metabolism. This
means:
A. The drug is rapidly distributed to the CNS
B. The drug has a high volume of distribution
C. The drug is activated in the kidneys before systemic circulation
D. A significant portion of the drug is metabolized in the liver before reaching
systemic circulation
E. The drug is primarily eliminated through bile
Correct Answer: D – A significant portion of the drug is metabolized in the
liver before reaching systemic circulation
EXPERT RATIONALE: First-pass metabolism occurs when an orally administered
drug is absorbed from the GI tract and passes through the portal circulation to the
liver, where it undergoes significant biotransformation before reaching systemic
circulation, reducing bioavailability.
,4. Which of the following best defines bioavailability?
A. The rate at which a drug is eliminated from the body
B. The ability of a drug to bind to its receptor
C. The time required to reach peak plasma concentration
D. The percentage of drug that reaches the target organ
E. The fraction of an administered drug that reaches systemic circulation in
an unchanged form
Correct Answer: E – The fraction of an administered drug that reaches
systemic circulation in an unchanged form
EXPERT RATIONALE: Bioavailability (F) reflects how much of the administered
dose actually reaches systemic circulation. IV administration yields 100%
bioavailability; oral bioavailability is reduced by first-pass metabolism and
incomplete absorption.
5. An APRN prescribes a loading dose for a patient. The primary reason for a
loading dose is to:
A. Reduce the risk of drug toxicity
B. Prolong the drug's half-life
C. Decrease the volume of distribution
D. Minimize first-pass metabolism
E. Rapidly achieve therapeutic plasma concentrations
Correct Answer: E – Rapidly achieve therapeutic plasma concentrations
EXPERT RATIONALE: A loading dose is a higher initial dose given to quickly
bring plasma drug levels to the therapeutic range, especially for drugs with long
half-lives where waiting for steady state would delay clinical effect.
, 6. Which cytochrome P450 enzyme is responsible for metabolizing the
majority of clinically used drugs?
A. CYP1A2
B. CYP2C9
C. CYP2D6
D. CYP2E1
E. CYP3A4
Correct Answer: E – CYP3A4
EXPERT RATIONALE: CYP3A4 is the most abundant hepatic and intestinal CYP
enzyme and is responsible for metabolizing approximately 50% of all clinically used
drugs. It is a common site for drug–drug interactions.
7. A patient on warfarin is started on rifampin. What is the expected
pharmacokinetic interaction?
A. Rifampin inhibits CYP2C9, increasing warfarin levels
B. Rifampin displaces warfarin from plasma proteins
C. Rifampin decreases warfarin absorption
D. Rifampin inhibits renal elimination of warfarin
E. Rifampin induces CYP enzymes, decreasing warfarin plasma levels
Correct Answer: E – Rifampin induces CYP enzymes, decreasing warfarin
plasma levels
EXPERT RATIONALE: Rifampin is a potent inducer of CYP3A4 and CYP2C9.
When co-administered with warfarin (metabolized by CYP2C9), rifampin increases
warfarin metabolism, lowering plasma levels and reducing anticoagulant effect,
increasing clotting risk.
